Latest Cancer vaccine Stories
WORCESTER, Mass. and TORONTO, Oct.
Management Responds To Inquiries Concerning Discovery Capabilities For Anti-Ebola Treatments SAN DIEGO, Oct. 21, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.
LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS The global cancer immunotherapies market reached $30.8 billion in 2012.
Robust Clinical Development Programs Across Sellas' Portfolio of Drugs and Biologics ZUG, Switzerland and NEW YORK, Oct.
TUBINGEN, Germany, October 14, 2014 /PRNewswire/ -- Regulatory authority approves clinical trial for Glioma Actively Personalized
SAN DIEGO, Oct. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.
Program Funded by the National Cancer Institute (NCI) CHARLOTTESVILLE, Va., Oct.
LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy.
SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S.
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics LOS
- In medieval musical notation, a sign or neume denoting a shake or trill.